NeoPharm (NEOL) Signs IL-13 Related CRADA with National Institute Of Neurological Disorders/ National Institutes of Health (NIH) for Research on the Therapeutic Agent for Untreatable Brain Diseases  
10/15/2008 9:55:32 AM

LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (NASDAQ: NEOL), today announced that the Company has signed a Cooperative Research and Development Agreement (the “CRADA”) with the National Institute of Neurological Diseases and Stroke (NINDS), a part of the National Institutes of Health (NIH) for research on a therapeutic agent for untreatable brain diseases in humans.